Global Flu Vaccine Market research

Flu Vaccine Comprehensive Study by Type (Whole Virus Vaccines, Split Virus Vaccines, Subunit Vaccines, Live Attenuated Virus Vaccines), Application (For Children (6 months to 3 years), For Adults and Children over 3 years), Vaccine (Trivalent, Quadrivalent) Players and Region - Global Market Outlook to 2028

Flu Vaccine Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Flu Vaccine Market Scope
According to the World Health Organization (WHO), 2018, Influenza cases related to hospitalization ranges in 3-5 million cases for severe illness, whereas Deaths related to Influenza are about 290,000 to 650,000. The unhealthy food habits of people coupled with seasonal outbreaks have accelerated the growth of Pandemic Vaccine production with the novel Vaccine Technology across Emerging countries. The influenza virus, also called flu, is a contagious respiratory illness caused by Influenza viruses that infect the nose, throat, and sometimes the lungs. It can cause mild to severe illness, and at times can lead to death. A Flu vaccine is a combination of three Influenza viruses namely, Influenza type A with H3N2 virus strain, Influenza type A with H1N1 virus strain and Influenza type B virus strain. Vaccine available in the market such as Quadrivalent Influenza Vaccine (split virion, inactivated) is indicated for active immunization of adults and children from 6 months of age and older for the prevention of influenza disease caused by the two Influenza A virus subtypes and the two Influenza B virus types contained in the vaccine.



The market is fragmented with numerous top-notch International manufacturers who are involved in adopting new strategies for flu vaccine and are investing heavily for the market. For Instance, In November 2018, Seqirus Announced USD 140 Million for Manufacturing & Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines. The big shot vaccine manufacturers are also focused upon acquiring new technologies and strengthening their presence in the market by collaborating with or acquiring small and medium-sized biotech companies that have strong vaccine candidates in their pipeline. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Flu Vaccine market throughout the predicted period.

CSL Limited (Australia), GlaxoSmithKline plc (United Kingdom), Sanofi Pasteur (France), Mylan N.V (United States), AstraZeneca PLC (United Kingdom), Pfizer Inc. (United States), Johnson & Johnson (United States) and Sinovac Biotec Ltd. (China) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Novartis AG (Switzerland), MedImmune (United States), Solvay (Belgium) and Sequirus Limited (United Kingdom).

Segmentation Overview
The study have segmented the market of Global Flu Vaccine market by Type (Whole Virus Vaccines, Split Virus Vaccines, Subunit Vaccines and Live Attenuated Virus Vaccines), by Application (For Children (6 months to 3 years) and For Adults and Children over 3 years) and Region with country level break-up.

On the basis of geography, the market of Flu Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2022.

Influencing Trend:
High Demand for the Quadrivalent Vaccine due to inexpensive nature & also the vaccine got approval from the Food & Drug Administration in 2017.

Market Growth Drivers:
The Emergent Government Policies and Innovations in Influenza Vaccine, Increasing Disease Awareness on Influenza Caused By the Threat of A Pandemic Influenza Outbreak, Wide Vaccination Coverage for Influenza Virus and The aging population and increasing prevalence of chronic diseases

Challenges:
Trivalent vaccines did not cover the entire Influenza type B virus.

Restraints:
Varying demand & Limited Production Capacity, High Level of Required Investment and Strict Regulations is presenting barriers to the New Entrants of The Market.

Opportunities:
Various companies have their on-going activities for newer technological development Novel Influenza vaccine helping the market to revolutionize.

Market Leaders and their Expansionary Development Strategies
WHO and its partners “Global Influenza Strategy” launched in 2018. Aligned with the general programme of work 2019-2023 (GPW13), the new strategy that will help in developing seasonal influenza prevention and control capacities. and These national efforts, in turn, will build greater global preparedness for the next pandemic. Globally, the strategy will focus on research and innovation. This will include improved influenza modelling and forecasting, along with the development of new vaccines, including a possible universal Influenza vaccine.
On September 27, 2018, the Centers for Disease Control and Prevention (CDC) and the National Foundation for Infectious Diseases (NFID) along with other Public health and Medical groups held a 2018-2019 Flu Vaccine Campaign.


Key Target Audience
Influenza Vaccine Manufacturers, Government & Regulatory Bodies, Research Organizations, Potential Investors, Downstream Vendors and Pharmaceutical Companies

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Type
  • Whole Virus Vaccines
  • Split Virus Vaccines
  • Subunit Vaccines
  • Live Attenuated Virus Vaccines
By Application
  • For Children (6 months to 3 years)
  • For Adults and Children over 3 years
By Vaccine
  • Trivalent
  • Quadrivalent

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Emergent Government Policies and Innovations in Influenza Vaccine
      • 3.2.2. Increasing Disease Awareness on Influenza Caused By the Threat of A Pandemic Influenza Outbreak
      • 3.2.3. Wide Vaccination Coverage for Influenza Virus
      • 3.2.4. The aging population and increasing prevalence of chronic diseases
    • 3.3. Market Challenges
      • 3.3.1. Trivalent vaccines did not cover the entire Influenza type B virus.
    • 3.4. Market Trends
      • 3.4.1. High Demand for the Quadrivalent Vaccine due to inexpensive nature & also the vaccine got approval from the Food & Drug Administration in 2017.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Flu Vaccine, by Type, Application, Vaccine and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Flu Vaccine (Value)
      • 5.2.1. Global Flu Vaccine by: Type (Value)
        • 5.2.1.1. Whole Virus Vaccines
        • 5.2.1.2. Split Virus Vaccines
        • 5.2.1.3. Subunit Vaccines
        • 5.2.1.4. Live Attenuated Virus Vaccines
      • 5.2.2. Global Flu Vaccine by: Application (Value)
        • 5.2.2.1. For Children (6 months to 3 years)
        • 5.2.2.2. For Adults and Children over 3 years
      • 5.2.3. Global Flu Vaccine by: Vaccine (Value)
        • 5.2.3.1. Trivalent
        • 5.2.3.2. Quadrivalent
      • 5.2.4. Global Flu Vaccine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Flu Vaccine (Volume)
      • 5.3.1. Global Flu Vaccine by: Type (Volume)
        • 5.3.1.1. Whole Virus Vaccines
        • 5.3.1.2. Split Virus Vaccines
        • 5.3.1.3. Subunit Vaccines
        • 5.3.1.4. Live Attenuated Virus Vaccines
      • 5.3.2. Global Flu Vaccine by: Application (Volume)
        • 5.3.2.1. For Children (6 months to 3 years)
        • 5.3.2.2. For Adults and Children over 3 years
      • 5.3.3. Global Flu Vaccine by: Vaccine (Volume)
        • 5.3.3.1. Trivalent
        • 5.3.3.2. Quadrivalent
      • 5.3.4. Global Flu Vaccine Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Flu Vaccine (Price)
      • 5.4.1. Global Flu Vaccine by: Type (Price)
  • 6. Flu Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. CSL Limited (Australia)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi Pasteur (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan N.V (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca PLC (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sinovac Biotec Ltd. (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Flu Vaccine Sale, by Type, Application, Vaccine and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Flu Vaccine (Value)
      • 7.2.1. Global Flu Vaccine by: Type (Value)
        • 7.2.1.1. Whole Virus Vaccines
        • 7.2.1.2. Split Virus Vaccines
        • 7.2.1.3. Subunit Vaccines
        • 7.2.1.4. Live Attenuated Virus Vaccines
      • 7.2.2. Global Flu Vaccine by: Application (Value)
        • 7.2.2.1. For Children (6 months to 3 years)
        • 7.2.2.2. For Adults and Children over 3 years
      • 7.2.3. Global Flu Vaccine by: Vaccine (Value)
        • 7.2.3.1. Trivalent
        • 7.2.3.2. Quadrivalent
      • 7.2.4. Global Flu Vaccine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Flu Vaccine (Volume)
      • 7.3.1. Global Flu Vaccine by: Type (Volume)
        • 7.3.1.1. Whole Virus Vaccines
        • 7.3.1.2. Split Virus Vaccines
        • 7.3.1.3. Subunit Vaccines
        • 7.3.1.4. Live Attenuated Virus Vaccines
      • 7.3.2. Global Flu Vaccine by: Application (Volume)
        • 7.3.2.1. For Children (6 months to 3 years)
        • 7.3.2.2. For Adults and Children over 3 years
      • 7.3.3. Global Flu Vaccine by: Vaccine (Volume)
        • 7.3.3.1. Trivalent
        • 7.3.3.2. Quadrivalent
      • 7.3.4. Global Flu Vaccine Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Flu Vaccine (Price)
      • 7.4.1. Global Flu Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Flu Vaccine: by Type(USD Million)
  • Table 2. Flu Vaccine Whole Virus Vaccines , by Region USD Million (2017-2022)
  • Table 3. Flu Vaccine Split Virus Vaccines , by Region USD Million (2017-2022)
  • Table 4. Flu Vaccine Subunit Vaccines , by Region USD Million (2017-2022)
  • Table 5. Flu Vaccine Live Attenuated Virus Vaccines , by Region USD Million (2017-2022)
  • Table 6. Flu Vaccine: by Application(USD Million)
  • Table 7. Flu Vaccine For Children (6 months to 3 years) , by Region USD Million (2017-2022)
  • Table 8. Flu Vaccine For Adults and Children over 3 years , by Region USD Million (2017-2022)
  • Table 9. Flu Vaccine: by Vaccine(USD Million)
  • Table 10. Flu Vaccine Trivalent , by Region USD Million (2017-2022)
  • Table 11. Flu Vaccine Quadrivalent , by Region USD Million (2017-2022)
  • Table 12. South America Flu Vaccine, by Country USD Million (2017-2022)
  • Table 13. South America Flu Vaccine, by Type USD Million (2017-2022)
  • Table 14. South America Flu Vaccine, by Application USD Million (2017-2022)
  • Table 15. South America Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 16. Brazil Flu Vaccine, by Type USD Million (2017-2022)
  • Table 17. Brazil Flu Vaccine, by Application USD Million (2017-2022)
  • Table 18. Brazil Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 19. Argentina Flu Vaccine, by Type USD Million (2017-2022)
  • Table 20. Argentina Flu Vaccine, by Application USD Million (2017-2022)
  • Table 21. Argentina Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 22. Rest of South America Flu Vaccine, by Type USD Million (2017-2022)
  • Table 23. Rest of South America Flu Vaccine, by Application USD Million (2017-2022)
  • Table 24. Rest of South America Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 25. Asia Pacific Flu Vaccine, by Country USD Million (2017-2022)
  • Table 26. Asia Pacific Flu Vaccine, by Type USD Million (2017-2022)
  • Table 27. Asia Pacific Flu Vaccine, by Application USD Million (2017-2022)
  • Table 28. Asia Pacific Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 29. China Flu Vaccine, by Type USD Million (2017-2022)
  • Table 30. China Flu Vaccine, by Application USD Million (2017-2022)
  • Table 31. China Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 32. Japan Flu Vaccine, by Type USD Million (2017-2022)
  • Table 33. Japan Flu Vaccine, by Application USD Million (2017-2022)
  • Table 34. Japan Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 35. India Flu Vaccine, by Type USD Million (2017-2022)
  • Table 36. India Flu Vaccine, by Application USD Million (2017-2022)
  • Table 37. India Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 38. South Korea Flu Vaccine, by Type USD Million (2017-2022)
  • Table 39. South Korea Flu Vaccine, by Application USD Million (2017-2022)
  • Table 40. South Korea Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 41. Taiwan Flu Vaccine, by Type USD Million (2017-2022)
  • Table 42. Taiwan Flu Vaccine, by Application USD Million (2017-2022)
  • Table 43. Taiwan Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 44. Australia Flu Vaccine, by Type USD Million (2017-2022)
  • Table 45. Australia Flu Vaccine, by Application USD Million (2017-2022)
  • Table 46. Australia Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 47. Rest of Asia-Pacific Flu Vaccine, by Type USD Million (2017-2022)
  • Table 48. Rest of Asia-Pacific Flu Vaccine, by Application USD Million (2017-2022)
  • Table 49. Rest of Asia-Pacific Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 50. Europe Flu Vaccine, by Country USD Million (2017-2022)
  • Table 51. Europe Flu Vaccine, by Type USD Million (2017-2022)
  • Table 52. Europe Flu Vaccine, by Application USD Million (2017-2022)
  • Table 53. Europe Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 54. Germany Flu Vaccine, by Type USD Million (2017-2022)
  • Table 55. Germany Flu Vaccine, by Application USD Million (2017-2022)
  • Table 56. Germany Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 57. France Flu Vaccine, by Type USD Million (2017-2022)
  • Table 58. France Flu Vaccine, by Application USD Million (2017-2022)
  • Table 59. France Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 60. Italy Flu Vaccine, by Type USD Million (2017-2022)
  • Table 61. Italy Flu Vaccine, by Application USD Million (2017-2022)
  • Table 62. Italy Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 63. United Kingdom Flu Vaccine, by Type USD Million (2017-2022)
  • Table 64. United Kingdom Flu Vaccine, by Application USD Million (2017-2022)
  • Table 65. United Kingdom Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 66. Netherlands Flu Vaccine, by Type USD Million (2017-2022)
  • Table 67. Netherlands Flu Vaccine, by Application USD Million (2017-2022)
  • Table 68. Netherlands Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 69. Rest of Europe Flu Vaccine, by Type USD Million (2017-2022)
  • Table 70. Rest of Europe Flu Vaccine, by Application USD Million (2017-2022)
  • Table 71. Rest of Europe Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 72. MEA Flu Vaccine, by Country USD Million (2017-2022)
  • Table 73. MEA Flu Vaccine, by Type USD Million (2017-2022)
  • Table 74. MEA Flu Vaccine, by Application USD Million (2017-2022)
  • Table 75. MEA Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 76. Middle East Flu Vaccine, by Type USD Million (2017-2022)
  • Table 77. Middle East Flu Vaccine, by Application USD Million (2017-2022)
  • Table 78. Middle East Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 79. Africa Flu Vaccine, by Type USD Million (2017-2022)
  • Table 80. Africa Flu Vaccine, by Application USD Million (2017-2022)
  • Table 81. Africa Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 82. North America Flu Vaccine, by Country USD Million (2017-2022)
  • Table 83. North America Flu Vaccine, by Type USD Million (2017-2022)
  • Table 84. North America Flu Vaccine, by Application USD Million (2017-2022)
  • Table 85. North America Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 86. United States Flu Vaccine, by Type USD Million (2017-2022)
  • Table 87. United States Flu Vaccine, by Application USD Million (2017-2022)
  • Table 88. United States Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 89. Canada Flu Vaccine, by Type USD Million (2017-2022)
  • Table 90. Canada Flu Vaccine, by Application USD Million (2017-2022)
  • Table 91. Canada Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 92. Mexico Flu Vaccine, by Type USD Million (2017-2022)
  • Table 93. Mexico Flu Vaccine, by Application USD Million (2017-2022)
  • Table 94. Mexico Flu Vaccine, by Vaccine USD Million (2017-2022)
  • Table 95. Flu Vaccine Sales: by Type(K Units)
  • Table 96. Flu Vaccine Sales Whole Virus Vaccines , by Region K Units (2017-2022)
  • Table 97. Flu Vaccine Sales Split Virus Vaccines , by Region K Units (2017-2022)
  • Table 98. Flu Vaccine Sales Subunit Vaccines , by Region K Units (2017-2022)
  • Table 99. Flu Vaccine Sales Live Attenuated Virus Vaccines , by Region K Units (2017-2022)
  • Table 100. Flu Vaccine Sales: by Application(K Units)
  • Table 101. Flu Vaccine Sales For Children (6 months to 3 years) , by Region K Units (2017-2022)
  • Table 102. Flu Vaccine Sales For Adults and Children over 3 years , by Region K Units (2017-2022)
  • Table 103. Flu Vaccine Sales: by Vaccine(K Units)
  • Table 104. Flu Vaccine Sales Trivalent , by Region K Units (2017-2022)
  • Table 105. Flu Vaccine Sales Quadrivalent , by Region K Units (2017-2022)
  • Table 106. South America Flu Vaccine Sales, by Country K Units (2017-2022)
  • Table 107. South America Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 108. South America Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 109. South America Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 110. Brazil Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 111. Brazil Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 112. Brazil Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 113. Argentina Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 114. Argentina Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 115. Argentina Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 116. Rest of South America Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 117. Rest of South America Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 118. Rest of South America Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 119. Asia Pacific Flu Vaccine Sales, by Country K Units (2017-2022)
  • Table 120. Asia Pacific Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 121. Asia Pacific Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 122. Asia Pacific Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 123. China Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 124. China Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 125. China Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 126. Japan Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 127. Japan Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 128. Japan Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 129. India Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 130. India Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 131. India Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 132. South Korea Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 133. South Korea Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 134. South Korea Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 135. Taiwan Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 136. Taiwan Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 137. Taiwan Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 138. Australia Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 139. Australia Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 140. Australia Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 141. Rest of Asia-Pacific Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 142. Rest of Asia-Pacific Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 143. Rest of Asia-Pacific Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 144. Europe Flu Vaccine Sales, by Country K Units (2017-2022)
  • Table 145. Europe Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 146. Europe Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 147. Europe Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 148. Germany Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 149. Germany Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 150. Germany Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 151. France Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 152. France Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 153. France Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 154. Italy Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 155. Italy Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 156. Italy Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 157. United Kingdom Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 158. United Kingdom Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 159. United Kingdom Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 160. Netherlands Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 161. Netherlands Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 162. Netherlands Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 163. Rest of Europe Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 164. Rest of Europe Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 165. Rest of Europe Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 166. MEA Flu Vaccine Sales, by Country K Units (2017-2022)
  • Table 167. MEA Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 168. MEA Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 169. MEA Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 170. Middle East Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 171. Middle East Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 172. Middle East Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 173. Africa Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 174. Africa Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 175. Africa Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 176. North America Flu Vaccine Sales, by Country K Units (2017-2022)
  • Table 177. North America Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 178. North America Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 179. North America Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 180. United States Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 181. United States Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 182. United States Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 183. Canada Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 184. Canada Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 185. Canada Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 186. Mexico Flu Vaccine Sales, by Type K Units (2017-2022)
  • Table 187. Mexico Flu Vaccine Sales, by Application K Units (2017-2022)
  • Table 188. Mexico Flu Vaccine Sales, by Vaccine K Units (2017-2022)
  • Table 189. Flu Vaccine: by Type(USD/Units)
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Flu Vaccine: by Type(USD Million)
  • Table 199. Flu Vaccine Whole Virus Vaccines , by Region USD Million (2023-2028)
  • Table 200. Flu Vaccine Split Virus Vaccines , by Region USD Million (2023-2028)
  • Table 201. Flu Vaccine Subunit Vaccines , by Region USD Million (2023-2028)
  • Table 202. Flu Vaccine Live Attenuated Virus Vaccines , by Region USD Million (2023-2028)
  • Table 203. Flu Vaccine: by Application(USD Million)
  • Table 204. Flu Vaccine For Children (6 months to 3 years) , by Region USD Million (2023-2028)
  • Table 205. Flu Vaccine For Adults and Children over 3 years , by Region USD Million (2023-2028)
  • Table 206. Flu Vaccine: by Vaccine(USD Million)
  • Table 207. Flu Vaccine Trivalent , by Region USD Million (2023-2028)
  • Table 208. Flu Vaccine Quadrivalent , by Region USD Million (2023-2028)
  • Table 209. South America Flu Vaccine, by Country USD Million (2023-2028)
  • Table 210. South America Flu Vaccine, by Type USD Million (2023-2028)
  • Table 211. South America Flu Vaccine, by Application USD Million (2023-2028)
  • Table 212. South America Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 213. Brazil Flu Vaccine, by Type USD Million (2023-2028)
  • Table 214. Brazil Flu Vaccine, by Application USD Million (2023-2028)
  • Table 215. Brazil Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 216. Argentina Flu Vaccine, by Type USD Million (2023-2028)
  • Table 217. Argentina Flu Vaccine, by Application USD Million (2023-2028)
  • Table 218. Argentina Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 219. Rest of South America Flu Vaccine, by Type USD Million (2023-2028)
  • Table 220. Rest of South America Flu Vaccine, by Application USD Million (2023-2028)
  • Table 221. Rest of South America Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 222. Asia Pacific Flu Vaccine, by Country USD Million (2023-2028)
  • Table 223. Asia Pacific Flu Vaccine, by Type USD Million (2023-2028)
  • Table 224. Asia Pacific Flu Vaccine, by Application USD Million (2023-2028)
  • Table 225. Asia Pacific Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 226. China Flu Vaccine, by Type USD Million (2023-2028)
  • Table 227. China Flu Vaccine, by Application USD Million (2023-2028)
  • Table 228. China Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 229. Japan Flu Vaccine, by Type USD Million (2023-2028)
  • Table 230. Japan Flu Vaccine, by Application USD Million (2023-2028)
  • Table 231. Japan Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 232. India Flu Vaccine, by Type USD Million (2023-2028)
  • Table 233. India Flu Vaccine, by Application USD Million (2023-2028)
  • Table 234. India Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 235. South Korea Flu Vaccine, by Type USD Million (2023-2028)
  • Table 236. South Korea Flu Vaccine, by Application USD Million (2023-2028)
  • Table 237. South Korea Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 238. Taiwan Flu Vaccine, by Type USD Million (2023-2028)
  • Table 239. Taiwan Flu Vaccine, by Application USD Million (2023-2028)
  • Table 240. Taiwan Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 241. Australia Flu Vaccine, by Type USD Million (2023-2028)
  • Table 242. Australia Flu Vaccine, by Application USD Million (2023-2028)
  • Table 243. Australia Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 244. Rest of Asia-Pacific Flu Vaccine, by Type USD Million (2023-2028)
  • Table 245. Rest of Asia-Pacific Flu Vaccine, by Application USD Million (2023-2028)
  • Table 246. Rest of Asia-Pacific Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 247. Europe Flu Vaccine, by Country USD Million (2023-2028)
  • Table 248. Europe Flu Vaccine, by Type USD Million (2023-2028)
  • Table 249. Europe Flu Vaccine, by Application USD Million (2023-2028)
  • Table 250. Europe Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 251. Germany Flu Vaccine, by Type USD Million (2023-2028)
  • Table 252. Germany Flu Vaccine, by Application USD Million (2023-2028)
  • Table 253. Germany Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 254. France Flu Vaccine, by Type USD Million (2023-2028)
  • Table 255. France Flu Vaccine, by Application USD Million (2023-2028)
  • Table 256. France Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 257. Italy Flu Vaccine, by Type USD Million (2023-2028)
  • Table 258. Italy Flu Vaccine, by Application USD Million (2023-2028)
  • Table 259. Italy Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 260. United Kingdom Flu Vaccine, by Type USD Million (2023-2028)
  • Table 261. United Kingdom Flu Vaccine, by Application USD Million (2023-2028)
  • Table 262. United Kingdom Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 263. Netherlands Flu Vaccine, by Type USD Million (2023-2028)
  • Table 264. Netherlands Flu Vaccine, by Application USD Million (2023-2028)
  • Table 265. Netherlands Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 266. Rest of Europe Flu Vaccine, by Type USD Million (2023-2028)
  • Table 267. Rest of Europe Flu Vaccine, by Application USD Million (2023-2028)
  • Table 268. Rest of Europe Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 269. MEA Flu Vaccine, by Country USD Million (2023-2028)
  • Table 270. MEA Flu Vaccine, by Type USD Million (2023-2028)
  • Table 271. MEA Flu Vaccine, by Application USD Million (2023-2028)
  • Table 272. MEA Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 273. Middle East Flu Vaccine, by Type USD Million (2023-2028)
  • Table 274. Middle East Flu Vaccine, by Application USD Million (2023-2028)
  • Table 275. Middle East Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 276. Africa Flu Vaccine, by Type USD Million (2023-2028)
  • Table 277. Africa Flu Vaccine, by Application USD Million (2023-2028)
  • Table 278. Africa Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 279. North America Flu Vaccine, by Country USD Million (2023-2028)
  • Table 280. North America Flu Vaccine, by Type USD Million (2023-2028)
  • Table 281. North America Flu Vaccine, by Application USD Million (2023-2028)
  • Table 282. North America Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 283. United States Flu Vaccine, by Type USD Million (2023-2028)
  • Table 284. United States Flu Vaccine, by Application USD Million (2023-2028)
  • Table 285. United States Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 286. Canada Flu Vaccine, by Type USD Million (2023-2028)
  • Table 287. Canada Flu Vaccine, by Application USD Million (2023-2028)
  • Table 288. Canada Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 289. Mexico Flu Vaccine, by Type USD Million (2023-2028)
  • Table 290. Mexico Flu Vaccine, by Application USD Million (2023-2028)
  • Table 291. Mexico Flu Vaccine, by Vaccine USD Million (2023-2028)
  • Table 292. Flu Vaccine Sales: by Type(K Units)
  • Table 293. Flu Vaccine Sales Whole Virus Vaccines , by Region K Units (2023-2028)
  • Table 294. Flu Vaccine Sales Split Virus Vaccines , by Region K Units (2023-2028)
  • Table 295. Flu Vaccine Sales Subunit Vaccines , by Region K Units (2023-2028)
  • Table 296. Flu Vaccine Sales Live Attenuated Virus Vaccines , by Region K Units (2023-2028)
  • Table 297. Flu Vaccine Sales: by Application(K Units)
  • Table 298. Flu Vaccine Sales For Children (6 months to 3 years) , by Region K Units (2023-2028)
  • Table 299. Flu Vaccine Sales For Adults and Children over 3 years , by Region K Units (2023-2028)
  • Table 300. Flu Vaccine Sales: by Vaccine(K Units)
  • Table 301. Flu Vaccine Sales Trivalent , by Region K Units (2023-2028)
  • Table 302. Flu Vaccine Sales Quadrivalent , by Region K Units (2023-2028)
  • Table 303. South America Flu Vaccine Sales, by Country K Units (2023-2028)
  • Table 304. South America Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 305. South America Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 306. South America Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 307. Brazil Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 308. Brazil Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 309. Brazil Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 310. Argentina Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 311. Argentina Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 312. Argentina Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 313. Rest of South America Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 314. Rest of South America Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 315. Rest of South America Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 316. Asia Pacific Flu Vaccine Sales, by Country K Units (2023-2028)
  • Table 317. Asia Pacific Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 318. Asia Pacific Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 319. Asia Pacific Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 320. China Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 321. China Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 322. China Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 323. Japan Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 324. Japan Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 325. Japan Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 326. India Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 327. India Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 328. India Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 329. South Korea Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 330. South Korea Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 331. South Korea Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 332. Taiwan Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 333. Taiwan Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 334. Taiwan Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 335. Australia Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 336. Australia Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 337. Australia Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 338. Rest of Asia-Pacific Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 339. Rest of Asia-Pacific Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 340. Rest of Asia-Pacific Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 341. Europe Flu Vaccine Sales, by Country K Units (2023-2028)
  • Table 342. Europe Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 343. Europe Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 344. Europe Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 345. Germany Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 346. Germany Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 347. Germany Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 348. France Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 349. France Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 350. France Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 351. Italy Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 352. Italy Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 353. Italy Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 354. United Kingdom Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 355. United Kingdom Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 356. United Kingdom Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 357. Netherlands Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 358. Netherlands Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 359. Netherlands Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 360. Rest of Europe Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 361. Rest of Europe Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 362. Rest of Europe Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 363. MEA Flu Vaccine Sales, by Country K Units (2023-2028)
  • Table 364. MEA Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 365. MEA Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 366. MEA Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 367. Middle East Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 368. Middle East Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 369. Middle East Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 370. Africa Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 371. Africa Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 372. Africa Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 373. North America Flu Vaccine Sales, by Country K Units (2023-2028)
  • Table 374. North America Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 375. North America Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 376. North America Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 377. United States Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 378. United States Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 379. United States Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 380. Canada Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 381. Canada Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 382. Canada Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 383. Mexico Flu Vaccine Sales, by Type K Units (2023-2028)
  • Table 384. Mexico Flu Vaccine Sales, by Application K Units (2023-2028)
  • Table 385. Mexico Flu Vaccine Sales, by Vaccine K Units (2023-2028)
  • Table 386. Flu Vaccine: by Type(USD/Units)
  • Table 387. Research Programs/Design for This Report
  • Table 388. Key Data Information from Secondary Sources
  • Table 389. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Flu Vaccine: by Type USD Million (2017-2022)
  • Figure 5. Global Flu Vaccine: by Application USD Million (2017-2022)
  • Figure 6. Global Flu Vaccine: by Vaccine USD Million (2017-2022)
  • Figure 7. South America Flu Vaccine Share (%), by Country
  • Figure 8. Asia Pacific Flu Vaccine Share (%), by Country
  • Figure 9. Europe Flu Vaccine Share (%), by Country
  • Figure 10. MEA Flu Vaccine Share (%), by Country
  • Figure 11. North America Flu Vaccine Share (%), by Country
  • Figure 12. Global Flu Vaccine: by Type K Units (2017-2022)
  • Figure 13. Global Flu Vaccine: by Application K Units (2017-2022)
  • Figure 14. Global Flu Vaccine: by Vaccine K Units (2017-2022)
  • Figure 15. South America Flu Vaccine Share (%), by Country
  • Figure 16. Asia Pacific Flu Vaccine Share (%), by Country
  • Figure 17. Europe Flu Vaccine Share (%), by Country
  • Figure 18. MEA Flu Vaccine Share (%), by Country
  • Figure 19. North America Flu Vaccine Share (%), by Country
  • Figure 20. Global Flu Vaccine: by Type USD/Units (2017-2022)
  • Figure 21. Global Flu Vaccine share by Players 2022 (%)
  • Figure 22. Global Flu Vaccine share by Players (Top 3) 2022(%)
  • Figure 23. Global Flu Vaccine share by Players (Top 5) 2022(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 26. CSL Limited (Australia) Revenue: by Geography 2022
  • Figure 27. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 29. Sanofi Pasteur (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi Pasteur (France) Revenue: by Geography 2022
  • Figure 31. Mylan N.V (United States) Revenue, Net Income and Gross profit
  • Figure 32. Mylan N.V (United States) Revenue: by Geography 2022
  • Figure 33. AstraZeneca PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. AstraZeneca PLC (United Kingdom) Revenue: by Geography 2022
  • Figure 35. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 37. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 38. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 39. Sinovac Biotec Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 40. Sinovac Biotec Ltd. (China) Revenue: by Geography 2022
  • Figure 41. Global Flu Vaccine: by Type USD Million (2023-2028)
  • Figure 42. Global Flu Vaccine: by Application USD Million (2023-2028)
  • Figure 43. Global Flu Vaccine: by Vaccine USD Million (2023-2028)
  • Figure 44. South America Flu Vaccine Share (%), by Country
  • Figure 45. Asia Pacific Flu Vaccine Share (%), by Country
  • Figure 46. Europe Flu Vaccine Share (%), by Country
  • Figure 47. MEA Flu Vaccine Share (%), by Country
  • Figure 48. North America Flu Vaccine Share (%), by Country
  • Figure 49. Global Flu Vaccine: by Type K Units (2023-2028)
  • Figure 50. Global Flu Vaccine: by Application K Units (2023-2028)
  • Figure 51. Global Flu Vaccine: by Vaccine K Units (2023-2028)
  • Figure 52. South America Flu Vaccine Share (%), by Country
  • Figure 53. Asia Pacific Flu Vaccine Share (%), by Country
  • Figure 54. Europe Flu Vaccine Share (%), by Country
  • Figure 55. MEA Flu Vaccine Share (%), by Country
  • Figure 56. North America Flu Vaccine Share (%), by Country
  • Figure 57. Global Flu Vaccine: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • CSL Limited (Australia)
  • GlaxoSmithKline plc (United Kingdom)
  • Sanofi Pasteur (France)
  • Mylan N.V (United States)
  • AstraZeneca PLC (United Kingdom)
  • Pfizer Inc. (United States)
  • Johnson & Johnson (United States)
  • Sinovac Biotec Ltd. (China)
Additional players considered in the study are as follows:
Novartis AG (Switzerland) , MedImmune (United States) , Solvay (Belgium) , Sequirus Limited (United Kingdom)
Select User Access Type

Key Highlights of Report


Jun 2023 212 Pages 55 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Flu Vaccine Market research Quantitative research analysis
Global Flu Vaccine Market research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Flu Vaccine study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Flu Vaccine Market is gaining popularity and expected to see strong valuation by 2028 .
According to AMA, the Global Flu Vaccine market is expected to see growth rate of xx%.
The Flu Vaccine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Flu Vaccine Market research Report?

Have a Query? Click Here

Other Related Reports

Vascular Graft Comprehensive Study by Raw Material (Polyester, EPTFE, Polyurethane, Biosyntheti), Indication (EVAR (Abdominal Aneurysm Repair & Thoracic Aneurysm0, Peripheral Vascular Repair, Hemodia...
$ 3450
Hirudin Comprehensive Study by Type (Natural Hirudin, Recombinant Hirudin), Disease Indication (Heparin-Induced Thrombocytopenia, Unstable Angina, Tumors, Others) Players and Region - Global Market O...
$ 3500
Prednisolone Acetate Comprehensive Study by Type (Prednisolone Acetate Tablet, Prednisolone Acetate Liquid, Prednisolone Acetate Emulsifiable Paste), Application (Hypersensitivity Disease, Autoimmune...
$ 3450
Sacral Nerve Stimulation Comprehensive Study by Type (Implantable, External), Application (Urinary & Fecal Incontinence, Urge Incontinence, Chronic Anal Fissure, Others), End User (Hospitals, Ambulat...
$ 3350
Scleroderma Diagnostics and Therapeutics Comprehensive Study by Application (Hospitals, Clinics), Diagnostics (Antibodies Tests/Blood Tests, Capillaroscopy, Cardiac Diagnosis, Gastrointestinal Diagno...
$ 3750
Renal Anemia Therapeutics Comprehensive Study by Type (DS-1093, EPO-018B, FG-2216, JTZ-951, MDGN-201), Application (Hospital, Research Center, Clinic), Mode of Administration (Oral, Parenteral) Playe...
$ 3500